A Study to Assess the Safety and Efficacy of UNO - Ultra High Concentration Nitric Oxide Injection in Combination With PD-1 Inhibitors Into Unresectable Solid Primary or Metastatic Tumors
brief summary
This is a Phase 1, open-label, dose-escalation and dose-expansion study comprised of 2 parts: Phase 1a - a single treatment session, an evaluation period of 21±3 days, and safety and survival follow-up period of up to 12 weeks post-treatment, and Phase 1b - a single treatment session followed by PD-1 inhibitors treatment cycles, in PD-1 single agent progressors, to evaluate safety, overall response rate, duration of response, progression free survival, and overall survival follow-up until disease progression or death.
detailed description
The purpose of this Phase 1 study is to initiate clinical development of UNO in patients with unresectable cutaneous or subcutaneous primary or metastatic solid tumors that are not amenable or have failed standard treatment, for which no therapy of proven efficacy exists, or which has progressed despite standard therapy. This study of UNO treatment will consist of 2 parts: a dose-escalation part to establish a safe and tolerable dose (maximum tolerate dose \[MTD\] and/or optimal biological dose \[OBD\] leading to a recommended Phase 2 dose \[RP2D\]) of UNO in patients with primary or metastatic unresectable cutaneous or subcutaneous solid tumors (Phase 1a), and a dose expansion phase of 25,000 ppm in combination with PD-1 inhibitor (Phase 1b) which may be initiated at the Sponsor's discretion in parallel with the Phase 1a. This study will be the basis for future studies.
official title
A Phase 1, Open-Label, Dose Escalation and Dose in Combination With PD-1 Inhibitors Expansion Study to Assess the Safety and Efficacy of UNO - Ultra High Concentration Nitric Oxide Injection Into Unresectable Solid Cutaneous/Subcutaneous Primary or Metastatic Tumors